Literature DB >> 30134646

Ocular Melanoma Recurrence Presenting as Cholestatic Jaundice due to Periampullary Area Metastases.

Sotiris Anastasiadis1, Andreas Xanthis1, Jannis Kountouras1, Panagiotis Katsinelos1.   

Abstract

Entities:  

Year:  2018        PMID: 30134646      PMCID: PMC6182291          DOI: 10.5946/ce.2018.061

Source DB:  PubMed          Journal:  Clin Endosc        ISSN: 2234-2400


× No keyword cloud information.
A 76-year-old woman presented with complaints of pruritus and painless jaundice. She had undergone radical resection of a stage IIB retinal melanoma followed by chemotherapy and immunotherapy 5 years before and is free of disease in last 3 years. On admission, she had a total bilirubin level of 9.6 mg/dL (direct, 6.3 mg/dL) and highly elevated cholestatic enzymes. An abdominal computed tomography revealed dilation of the intrahepatic and extrahepatic biliary systems, as well as the main pancreatic duct up to the level of the major papilla. No evidence of metastases to the liver or other organs were observed. An endoscopic retrograde cholangiopancreatography image demonstrated a swollen major papilla with a blackish hue at the periampullary area and a black volcano-like lesion near the major papilla (Fig. 1). Conventional cannulation of the common bile duct was impossible. Therefore, a suprapapillary sphincterotomy was performed. Many biopsy specimens were taken through sphincterotomy, from the volcano-like lesion. A palliative 10-Fr, 7-cm plastic stent was placed (Fig. 1). Histological examination of the biopsies with hematoxylin-eosin staining revealed spindle-shaped cells with cytoplasmic brightness and nuclear atypia consistent with the diagnosis of melanoma (Fig. 2). Immunohistochemistry was positive for melan-A protein antigen, confirming the diagnosis of metastatic malignant melanoma (Fig. 2). An outpatient positron emission tomography scan showed numerous areas from the chest to the abdomen with hypermetabolic activity indicating neoplasia. She underwent palliative chemotherapy but died 6 months later.
Fig. 1.

Duodenoscopy image showing a periampullary area with blackish hue, a plastic stent inserted in the common bile duct, and a black volcano-like lesion near the major papilla.

Fig. 2.

(A) Stranded proliferation of spindle-shaped cells with cytoplasmic brightness and nuclear atypia (hematoxylin-eosin, original magnification ×200). (B) Immunohistochemical staining showing positivity for melan-A.

Malignant melanoma is among the most threatening malignancies and a highly metastatic cancer [1]. Gastrointestinal tract metastases involve mostly the small intestine and colon [2]. Cholestatic jaundice due to major papilla or periampullary area metastases is rare [3]. The endoscopic findings of melanomas metastases frequently comprise a black volcano-like lesion or infiltrates in the submucosa and extend for variable depths into the wall [4]. Amelanotic lesions with variable appearance are rare entities [2,4]. The diagnosis of malignancy is established by immunohistochemical analysis of biopsy specimens; the tumor marker S-100 protein positivity ranges from 30% to 100%, melan-A protein antigen has high specificity (100%), and HMB-45 protein displays high specificity (100%) and sensitivity of 80%–90% [1].
  4 in total

1.  Malignant melanoma presenting as obstructive jaundice secondary to metastasis to the Ampulla of Vater.

Authors:  Joshua A Marks; Atul S Rao; David Loren; Agnes Witkiewicz; Michael J Mastrangelo; Adam C Berger
Journal:  JOP       Date:  2010-03-05

Review 2.  Primary and metastatic diseases in malignant melanoma of the gastrointestinal tract.

Authors:  L M Schuchter; R Green; D Fraker
Journal:  Curr Opin Oncol       Date:  2000-03       Impact factor: 3.645

Review 3.  Melanoma in the gastrointestinal tract.

Authors:  D Blecker; S Abraham; E E Furth; M L Kochman
Journal:  Am J Gastroenterol       Date:  1999-12       Impact factor: 10.864

4.  Metastatic tumors to the upper gastrointestinal tract: endoscopic experience.

Authors:  S C Kadakia; A Parker; L Canales
Journal:  Am J Gastroenterol       Date:  1992-10       Impact factor: 10.864

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.